JP2018516092A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516092A5 JP2018516092A5 JP2018503725A JP2018503725A JP2018516092A5 JP 2018516092 A5 JP2018516092 A5 JP 2018516092A5 JP 2018503725 A JP2018503725 A JP 2018503725A JP 2018503725 A JP2018503725 A JP 2018503725A JP 2018516092 A5 JP2018516092 A5 JP 2018516092A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- target
- rlx
- amino acid
- mgswx
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 129
- 229920001184 polypeptide Polymers 0.000 claims description 123
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 123
- 230000027455 binding Effects 0.000 claims description 104
- 206010028980 Neoplasm Diseases 0.000 claims description 56
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 41
- 201000011510 cancer Diseases 0.000 claims description 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 33
- 238000006467 substitution reaction Methods 0.000 claims description 28
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 24
- 235000001014 amino acid Nutrition 0.000 claims description 24
- 210000002865 immune cell Anatomy 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 108020001507 fusion proteins Proteins 0.000 claims description 16
- 102000037865 fusion proteins Human genes 0.000 claims description 16
- 230000009870 specific binding Effects 0.000 claims description 16
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 15
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 235000018417 cysteine Nutrition 0.000 claims description 12
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 10
- 230000004048 modification Effects 0.000 claims description 10
- 238000012986 modification Methods 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 8
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 8
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 230000003834 intracellular effect Effects 0.000 claims description 8
- 230000004068 intracellular signaling Effects 0.000 claims description 8
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 6
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 6
- 235000018102 proteins Nutrition 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 230000011664 signaling Effects 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- -1 DBDpp Proteins 0.000 claims description 5
- 230000000139 costimulatory effect Effects 0.000 claims description 5
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 102100026964 M1-specific T cell receptor beta chain Human genes 0.000 claims description 4
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 102100026882 Alpha-synuclein Human genes 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 3
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 3
- 229930186217 Glycolipid Natural products 0.000 claims description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 3
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 3
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 3
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 3
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 3
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 3
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims description 3
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims description 3
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 3
- 102000002698 KIR Receptors Human genes 0.000 claims description 3
- 108010043610 KIR Receptors Proteins 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 3
- 102000003735 Mesothelin Human genes 0.000 claims description 3
- 108090000015 Mesothelin Proteins 0.000 claims description 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 3
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims description 3
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 3
- 238000012737 microarray-based gene expression Methods 0.000 claims description 3
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 102100038078 CD276 antigen Human genes 0.000 claims description 2
- 101710185679 CD276 antigen Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102100035793 CD83 antigen Human genes 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 230000005809 anti-tumor immunity Effects 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 description 13
- 230000001472 cytotoxic effect Effects 0.000 description 13
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021068754A JP7244567B2 (ja) | 2015-04-06 | 2021-04-15 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
| JP2023007753A JP2023052563A (ja) | 2015-04-06 | 2023-01-23 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
| JP2024049923A JP2024075751A (ja) | 2015-04-06 | 2024-03-26 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562143772P | 2015-04-06 | 2015-04-06 | |
| US62/143,772 | 2015-04-06 | ||
| PCT/US2016/025868 WO2016164305A1 (en) | 2015-04-06 | 2016-04-04 | De novo binding domain containing polypeptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021068754A Division JP7244567B2 (ja) | 2015-04-06 | 2021-04-15 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516092A JP2018516092A (ja) | 2018-06-21 |
| JP2018516092A5 true JP2018516092A5 (enExample) | 2019-05-09 |
| JP6871232B2 JP6871232B2 (ja) | 2021-05-12 |
Family
ID=57072017
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018503725A Active JP6871232B2 (ja) | 2015-04-06 | 2016-04-04 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
| JP2018503726A Active JP6873101B2 (ja) | 2015-04-06 | 2016-04-04 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
| JP2021068754A Active JP7244567B2 (ja) | 2015-04-06 | 2021-04-15 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
| JP2023007753A Withdrawn JP2023052563A (ja) | 2015-04-06 | 2023-01-23 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
| JP2024049923A Pending JP2024075751A (ja) | 2015-04-06 | 2024-03-26 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018503726A Active JP6873101B2 (ja) | 2015-04-06 | 2016-04-04 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
| JP2021068754A Active JP7244567B2 (ja) | 2015-04-06 | 2021-04-15 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
| JP2023007753A Withdrawn JP2023052563A (ja) | 2015-04-06 | 2023-01-23 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
| JP2024049923A Pending JP2024075751A (ja) | 2015-04-06 | 2024-03-26 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (9) | US10647775B2 (enExample) |
| EP (3) | EP3280432B8 (enExample) |
| JP (5) | JP6871232B2 (enExample) |
| KR (2) | KR102788389B1 (enExample) |
| CN (4) | CN115160438A (enExample) |
| AU (4) | AU2016246426B2 (enExample) |
| BR (1) | BR112017021308A2 (enExample) |
| CA (2) | CA2981711A1 (enExample) |
| CY (1) | CY1124453T1 (enExample) |
| DK (2) | DK3280432T3 (enExample) |
| EA (1) | EA201792226A1 (enExample) |
| ES (2) | ES2866202T3 (enExample) |
| HR (1) | HRP20210498T1 (enExample) |
| HU (1) | HUE054435T2 (enExample) |
| IL (2) | IL254907B (enExample) |
| LT (1) | LT3280432T (enExample) |
| MX (2) | MX387517B (enExample) |
| PH (1) | PH12017501834B1 (enExample) |
| PL (1) | PL3280432T3 (enExample) |
| PT (1) | PT3280432T (enExample) |
| RS (1) | RS61907B1 (enExample) |
| SG (2) | SG10202007987QA (enExample) |
| SI (1) | SI3280432T1 (enExample) |
| SM (1) | SMT202100285T1 (enExample) |
| WO (3) | WO2016164308A1 (enExample) |
| ZA (1) | ZA201706875B (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| RS61907B1 (sr) * | 2015-04-06 | 2021-06-30 | Subdomain Llc | Polipeptidi koji sadrže de novo vezujući domen i njihova primena |
| WO2018075586A1 (en) * | 2016-10-18 | 2018-04-26 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof |
| AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CA3053275A1 (en) * | 2017-02-10 | 2018-08-16 | Dragonfly Therapeutics, Inc. | Proteins binding psma, nkg2d and cd16 |
| CN110461361A (zh) * | 2017-02-10 | 2019-11-15 | 蜻蜓治疗公司 | 结合bcma、nkg2d和cd16的蛋白 |
| CN110944661A (zh) | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| US11274141B2 (en) | 2017-05-10 | 2022-03-15 | Wellstat Immunotherapeutics, Llc | Enveloped virus resistant to complement inactivation for the treatment of cancer |
| CN107216395B (zh) * | 2017-07-03 | 2018-07-20 | 上海科医联创生物科技有限公司 | 一种tm4sf1特异性嵌合抗原受体及其应用 |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| AU2018338322B2 (en) * | 2017-09-23 | 2025-07-17 | Memorial Sloan Kettering Cancer Center | A33 antibody compositions and methods of using the same in radioimmunotherapy |
| ES3062820T3 (en) | 2017-11-08 | 2026-04-14 | L E A F Holdings Group Llc | Platinum complexes and uses thereof |
| TWI701259B (zh) * | 2017-11-09 | 2020-08-11 | 大陸商上海懷越生物科技有限公司 | ４﹘１ｂｂ抗體及其製備方法和應用 |
| RS67119B1 (sr) * | 2017-11-14 | 2025-09-30 | Arcellx Inc | Polipeptidi koji obuhvataju d domen i njihove upotrebe |
| US11464803B2 (en) | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
| KR20250070609A (ko) * | 2017-11-14 | 2025-05-20 | 아르셀엑스, 인크. | 다기능성 면역 세포 요법 |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| EP3749318A4 (en) | 2018-02-07 | 2022-07-06 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES |
| CA3090389A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| US12310966B2 (en) | 2018-02-07 | 2025-05-27 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| WO2019157129A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| EP3749314A4 (en) | 2018-02-07 | 2022-02-23 | L.E.A.F Holdings Group LLC | ALPHA-POLYGLUTAMATE METHOTREXATE AND ITS USES |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| US12350271B2 (en) | 2018-02-14 | 2025-07-08 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
| JP7462950B2 (ja) | 2018-02-14 | 2024-04-08 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | ガンマポリグルタミン酸化メトトレキセートおよびその使用 |
| WO2019160734A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| CA3090753A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| US20210017248A1 (en) * | 2018-03-16 | 2021-01-21 | The Regents Of The University Of California | Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells |
| CA3099450A1 (en) | 2018-05-08 | 2019-11-14 | Amgen Inc. | Bispecific antibodies with cleavable c-terminal charge-paired tags |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| GB201903479D0 (en) * | 2019-03-14 | 2019-05-01 | Univ Oxford Innovation Ltd | Polypeptide with enchanced rate of spontaneous isopeptide bond formation with it's peptide tag partner and uses thereof |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| CN113661240B (zh) * | 2019-04-02 | 2024-11-05 | 伊莱利利公司 | 选择和检测结合肽的方法 |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN111848733B (zh) * | 2019-04-30 | 2024-03-12 | 上海细胞治疗集团有限公司 | 一种多肽组合物及疫苗 |
| US12312607B2 (en) * | 2019-05-24 | 2025-05-27 | Avitide LLC | AAV9 affinity agents |
| JP7579812B2 (ja) | 2019-05-31 | 2024-11-08 | アイバイオ， インク． | メソスケールペプチドを操作するための機械学習ベースの装置およびそのための方法およびシステム |
| US20230000997A1 (en) | 2019-08-06 | 2023-01-05 | L.E.A.F. Holdings Group Llc | Processes of preparing polyglutamated antifolates and uses of their compositions |
| WO2021100585A1 (ja) * | 2019-11-20 | 2021-05-27 | 国立大学法人東海国立大学機構 | キメラ抗原受容体遺伝子改変リンパ球の調製方法 |
| WO2021115333A1 (zh) * | 2019-12-10 | 2021-06-17 | 苏州克睿基因生物科技有限公司 | 一种融合蛋白及表达此蛋白的工程化免疫细胞及其应用 |
| JP7512394B2 (ja) | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| CN111560391B (zh) * | 2020-05-21 | 2022-02-11 | 北京大学 | 一种蛋白质异质索烃的生物合成方法 |
| CN111732635B (zh) * | 2020-06-22 | 2022-03-22 | 中国医学科学院基础医学研究所 | 与cd123蛋白特异性结合的多肽、多肽复合物、共递送系统及其制备方法与应用 |
| CN116261567A (zh) * | 2020-07-03 | 2023-06-13 | 纽约市哥伦比亚大学理事会 | 多功能性正交蛋白嵌合体 |
| CN114380907B (zh) * | 2020-10-16 | 2024-06-18 | 中国科学院上海药物研究所 | 靶向cmtm6的纳米抗体及其制备方法和应用 |
| EP4281566A1 (en) * | 2021-01-20 | 2023-11-29 | Coding Bio Limited | Methods for high throughput screening of chimeric antigen receptors |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| MX2023011110A (es) | 2021-03-26 | 2023-11-23 | Arcellx Inc | Terapias de celulas inmunitarias multifuncionales. |
| CN118679180A (zh) | 2021-11-15 | 2024-09-20 | 阿奇利克斯股份有限公司 | 包含d结构域的多肽及其用途 |
| JP2025508721A (ja) * | 2022-02-18 | 2025-04-10 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | 細胞表面受容体のエピトープ操作 |
| WO2023177851A1 (en) * | 2022-03-17 | 2023-09-21 | Singular Immune, Inc | Composition and method of use recombinant fusion protein to generate car-immune cells |
| WO2023212602A2 (en) * | 2022-04-27 | 2023-11-02 | Board Of Regents, The University Of Texas System | Cd30 hinge and/or transmembrane domain-based chimeric antigen receptors |
| CN115028689B (zh) * | 2022-06-15 | 2023-05-30 | 浙江东方基因生物制品股份有限公司 | 特异性检测hpv6和hpv11的双特异性检测试剂盒 |
| CN116380854B (zh) * | 2023-03-06 | 2025-05-30 | 上海电力大学 | 一种基于荧光光谱快速检测水中微塑料污染的方法 |
| EP4724461A1 (en) * | 2023-06-07 | 2026-04-15 | The Broad Institute, Inc. | Engineered viral like particles (evlps) for the selective transduction of target cells |
| WO2025122460A1 (en) * | 2023-12-04 | 2025-06-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| AU7378096A (en) | 1995-09-28 | 1997-04-17 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
| DK0934526T3 (da) | 1996-10-08 | 2003-05-05 | Bisys B V U | Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål |
| US7763258B2 (en) | 1997-05-20 | 2010-07-27 | The Trustees Of The University Of Pennsylvania | Virus-like particles (VLPs) comprising heterologous multiple membrane spanning proteins |
| DE19802708A1 (de) | 1998-01-24 | 1999-07-29 | Hoechst Marion Roussel De Gmbh | Verwendung von hydroxypyridon-haltigen Puderzubereitungen zur Behandlung von Unterschenkel- und Druckgeschwüren |
| KR20010034512A (ko) | 1998-02-19 | 2001-04-25 | 베렌슨, 론 | 림프구 활성화 조절을 위한 조성물 및 그 방법 |
| US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
| ATE421976T1 (de) | 1999-05-18 | 2009-02-15 | Dyax Corp | Fab fragmentbibliotheken und verfahren für deren verwendung |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| EP1240337B1 (en) | 1999-12-24 | 2006-08-23 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| AU8822601A (en) | 2000-07-31 | 2002-02-13 | Biolex Inc | Expression of biologically active polypeptides in duckweed |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| CA2471551C (en) | 2001-12-27 | 2014-09-30 | Glycofi, Inc. | Methods to engineer mammalian-type carbohydrate structures |
| US20040009530A1 (en) | 2002-01-16 | 2004-01-15 | Wilson David S. | Engineered binding proteins |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US7314974B2 (en) | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
| CN1665934B (zh) | 2002-03-19 | 2010-05-26 | 国际植物研究所 | GNTIII(UDP-N乙酰葡萄糖胺:β-D-甘露糖苷β(1,4)-N-乙酰葡萄糖胺基-转移酶III)在植物中的表达 |
| DK1534830T3 (da) | 2002-09-06 | 2011-02-14 | Isogenica Ltd | In vito-peptid-ekspressionsbibliotek |
| EP1539966B1 (en) | 2002-09-12 | 2010-06-30 | Greenovation Biotech GmbH | Protein production method |
| WO2004057002A2 (en) | 2002-12-20 | 2004-07-08 | Greenovation Biotech Gmbh | Production of heterologous glycosylated proteins in bryophyte cells |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| CA2537273A1 (en) | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| US8377447B2 (en) | 2003-09-05 | 2013-02-19 | Oregon Health & Science University | Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells |
| EP1737971B1 (en) | 2004-01-20 | 2017-08-16 | Merus N.V. | Mixtures of binding proteins |
| AU2005274905B2 (en) | 2004-08-04 | 2010-12-23 | Mentrik Biotech, Llc | Variant Fc regions |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| CN101287503A (zh) * | 2005-08-03 | 2008-10-15 | Rq生物科技有限公司 | 用于诊断IgA和IgM介导的肾脏疾病的方法和组合物 |
| US20090220508A1 (en) | 2006-03-15 | 2009-09-03 | Alexion Pharmaceuticals, Inc. | Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement |
| WO2008052043A2 (en) | 2006-10-24 | 2008-05-02 | Cogenesys, Inc. | Opioid receptor agonist fusion proteins |
| GB0907251D0 (en) | 2009-04-28 | 2009-06-10 | Univ Leiden | Coplymers |
| US20120172419A1 (en) | 2009-09-15 | 2012-07-05 | Medical College Of Wisconsin Research Foundation Inc. | Reagents and methods for modulating cone photoreceptor activity |
| WO2012044999A2 (en) * | 2010-10-01 | 2012-04-05 | Ludwig Institute For Cancer Research Ltd. | Reversible protein multimers, methods for their production and use |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012167109A2 (en) | 2011-06-03 | 2012-12-06 | Massachusetts Eye & Ear Infirmary | Rpgrip1 gene therapy for leber congenital amaurosis |
| WO2014028776A1 (en) | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
| EP2899271B1 (en) * | 2012-09-21 | 2018-07-25 | Kaneka Corporation | Protein ligand for affinity isolation matrix |
| US9840539B2 (en) * | 2013-03-14 | 2017-12-12 | University Of Washington Through Its Center For Commercialization | High affinity digoxigenin binding proteins |
| WO2014138805A1 (en) | 2013-03-14 | 2014-09-18 | Csl Limited | Anti il-3r alpha agents and uses thereof |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| GB201306634D0 (en) | 2013-04-11 | 2013-05-29 | Univ Bristol | Cage-like particles |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| LT3137497T (lt) | 2014-05-02 | 2021-07-26 | Genzyme Corporation | Aav vektoriai, skirti tinklainės ir cns genų terapijai |
| US10201606B2 (en) | 2014-11-26 | 2019-02-12 | Miltenyi Biotec Gmbh | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
| US10800828B2 (en) | 2015-03-26 | 2020-10-13 | The Scripps Research Institute | Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer |
| RS61907B1 (sr) | 2015-04-06 | 2021-06-30 | Subdomain Llc | Polipeptidi koji sadrže de novo vezujući domen i njihova primena |
| KR20160126340A (ko) | 2015-04-23 | 2016-11-02 | 삼성전자주식회사 | 3중-나선 다발 단백질 및 이의 용도 |
| CN108473575B (zh) | 2015-11-13 | 2022-04-19 | 美国卫生和人力服务部 | 抗-bcma多肽和蛋白质 |
| LT3535392T (lt) | 2016-11-02 | 2024-04-25 | Universität Basel | Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje |
| CN107254447B (zh) | 2017-06-01 | 2020-10-16 | 刘未斌 | Anti AFP CAR-T细胞及其制备方法和应用 |
| KR20250070609A (ko) | 2017-11-14 | 2025-05-20 | 아르셀엑스, 인크. | 다기능성 면역 세포 요법 |
| US11464803B2 (en) | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
| RS67119B1 (sr) | 2017-11-14 | 2025-09-30 | Arcellx Inc | Polipeptidi koji obuhvataju d domen i njihove upotrebe |
| MX2023011110A (es) | 2021-03-26 | 2023-11-23 | Arcellx Inc | Terapias de celulas inmunitarias multifuncionales. |
| CN118679180A (zh) | 2021-11-15 | 2024-09-20 | 阿奇利克斯股份有限公司 | 包含d结构域的多肽及其用途 |
| CA3275338A1 (en) | 2022-11-29 | 2024-06-06 | Arcellx, Inc. | D-DOMAIN POLYPEPTIDES AND ASSOCIATED USES |
-
2016
- 2016-04-04 RS RS20210529A patent/RS61907B1/sr unknown
- 2016-04-04 CA CA2981711A patent/CA2981711A1/en active Pending
- 2016-04-04 SM SM20210285T patent/SMT202100285T1/it unknown
- 2016-04-04 KR KR1020177031697A patent/KR102788389B1/ko active Active
- 2016-04-04 DK DK16777107.0T patent/DK3280432T3/da active
- 2016-04-04 DK DK16777109.6T patent/DK3280433T3/da active
- 2016-04-04 SG SG10202007987QA patent/SG10202007987QA/en unknown
- 2016-04-04 US US15/564,319 patent/US10647775B2/en active Active
- 2016-04-04 ES ES16777107T patent/ES2866202T3/es active Active
- 2016-04-04 US US15/564,325 patent/US10662248B2/en active Active
- 2016-04-04 EP EP16777107.0A patent/EP3280432B8/en active Active
- 2016-04-04 SG SG11201708257UA patent/SG11201708257UA/en unknown
- 2016-04-04 AU AU2016246426A patent/AU2016246426B2/en active Active
- 2016-04-04 WO PCT/US2016/025880 patent/WO2016164308A1/en not_active Ceased
- 2016-04-04 PT PT167771070T patent/PT3280432T/pt unknown
- 2016-04-04 HU HUE16777107A patent/HUE054435T2/hu unknown
- 2016-04-04 LT LTEP16777107.0T patent/LT3280432T/lt unknown
- 2016-04-04 CN CN202210256708.8A patent/CN115160438A/zh active Pending
- 2016-04-04 CA CA2981616A patent/CA2981616C/en active Active
- 2016-04-04 MX MX2017012679A patent/MX387517B/es unknown
- 2016-04-04 PH PH1/2017/501834A patent/PH12017501834B1/en unknown
- 2016-04-04 EP EP21155053.8A patent/EP3903804A1/en active Pending
- 2016-04-04 HR HRP20210498TT patent/HRP20210498T1/hr unknown
- 2016-04-04 EA EA201792226A patent/EA201792226A1/ru unknown
- 2016-04-04 EP EP16777109.6A patent/EP3280433B1/en active Active
- 2016-04-04 KR KR1020257009799A patent/KR20250048140A/ko active Pending
- 2016-04-04 CN CN201680032015.3A patent/CN107921090A/zh active Pending
- 2016-04-04 CN CN201680032016.8A patent/CN107708720A/zh active Pending
- 2016-04-04 WO PCT/US2016/025868 patent/WO2016164305A1/en not_active Ceased
- 2016-04-04 JP JP2018503725A patent/JP6871232B2/ja active Active
- 2016-04-04 JP JP2018503726A patent/JP6873101B2/ja active Active
- 2016-04-04 ES ES16777109T patent/ES2901273T3/es active Active
- 2016-04-04 PL PL16777107T patent/PL3280432T3/pl unknown
- 2016-04-04 BR BR112017021308-7A patent/BR112017021308A2/pt not_active Application Discontinuation
- 2016-04-04 SI SI201631199T patent/SI3280432T1/sl unknown
- 2016-04-04 CN CN202510559733.7A patent/CN120424177A/zh active Pending
- 2016-04-05 WO PCT/US2016/026054 patent/WO2016164369A2/en not_active Ceased
- 2016-04-05 US US15/564,430 patent/US20180209983A1/en not_active Abandoned
-
2017
- 2017-10-02 MX MX2021013161A patent/MX2021013161A/es unknown
- 2017-10-06 IL IL254907A patent/IL254907B/en active IP Right Grant
- 2017-10-11 ZA ZA2017/06875A patent/ZA201706875B/en unknown
-
2020
- 2020-01-24 US US16/751,730 patent/US20200362046A1/en not_active Abandoned
- 2020-03-13 US US16/817,755 patent/US11008397B2/en active Active
- 2020-03-20 US US16/824,809 patent/US12528872B2/en active Active
-
2021
- 2021-02-09 AU AU2021200810A patent/AU2021200810B2/en active Active
- 2021-04-13 US US17/228,817 patent/US12358995B2/en active Active
- 2021-04-15 JP JP2021068754A patent/JP7244567B2/ja active Active
- 2021-04-27 IL IL282704A patent/IL282704A/en unknown
- 2021-06-03 CY CY20211100483T patent/CY1124453T1/el unknown
-
2022
- 2022-12-22 US US18/145,169 patent/US20240043550A1/en active Pending
-
2023
- 2023-01-23 JP JP2023007753A patent/JP2023052563A/ja not_active Withdrawn
- 2023-08-22 AU AU2023219820A patent/AU2023219820B2/en active Active
-
2024
- 2024-03-26 JP JP2024049923A patent/JP2024075751A/ja active Pending
-
2025
- 2025-04-23 AU AU2025202871A patent/AU2025202871A1/en active Pending
- 2025-06-06 US US19/231,210 patent/US20250353920A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516092A5 (enExample) | ||
| US11008376B2 (en) | Trifunctional T cell-antigen coupler and methods and uses thereof | |
| JP7487112B2 (ja) | Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| JP7068459B2 (ja) | Ｎｙｅｓｏ ｔｃｒ | |
| HRP20210498T1 (hr) | De novo vezujuća domena koja sadrži polipeptide i njihova upotreba | |
| EP3472205B1 (en) | Chimeric antigen receptor | |
| JP7227630B2 (ja) | Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用 | |
| US11878035B2 (en) | T cell-antigen coupler with various construct optimizations | |
| JP2020530989A5 (enExample) | ||
| JP7404279B2 (ja) | 様々な構築物最適化を備えたｔ細胞抗原カプラ | |
| JP2019534246A5 (enExample) | ||
| JP2017537622A5 (enExample) | ||
| JP2023512452A (ja) | Ｂｃｍａ指向性細胞免疫療法組成物および方法 | |
| JP2022510276A5 (enExample) | ||
| JP2024544559A5 (enExample) | ||
| JP2025527657A (ja) | Ｎｙ－ｅｓｏ－１特異的ｔ細胞受容体とキメラ共刺激受容体との組み合わせ物 | |
| JP7174144B2 (ja) | Ｈａ－１特異的ｔ細胞受容体およびその使用 | |
| JP2023542208A (ja) | Ｍａｇｅ－ａ３特異的ｔ細胞受容体およびその使用 | |
| CN115873801A (zh) | 工程化免疫细胞及其用途 | |
| JP2024535740A5 (enExample) | ||
| NZ736022B2 (en) | De novo binding domain containing polypeptides and uses thereof | |
| CA3090917C (en) | Nyeso tcr | |
| HK40054580A (en) | Trifunctional t cell-antigen coupler and methods and uses thereof | |
| NZ805407A (en) | D-domain containing polypeptides and uses thereof | |
| HK1234091A1 (en) | Trifunctional t cell-antigen coupler and methods and uses thereof |